COMMUNIQUÉS West-GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
02/03/2026
Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage [...]
SAB BIO to Participate in Upcoming Investor Conferences
02/03/2026
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Living with a Rare Disease: A Pastor’s Journey Finding the Right Care and Treatment for NF1-PN
02/03/2026
STAMFORD, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Did you know neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) is a rare genetic disorder that can cause tumors to grow along nerves, leading to pain, [...]
Health-ISAC Releases Its 2025 Annual Report
02/03/2026
Cultivating 15 Years of Global Health Sector Resilience ORLANDO, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center ( Health-ISAC ), the non-profit industry-led organization that [...]
Transactions in Connection with Share Buy-back Program
02/03/2026
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum [...]
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
02/03/2026
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief [...]
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
02/03/2026
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE [...]
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
02/03/2026
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Ardena Appoints Paul Edwards as Chief People Officer
02/03/2026
Ghent, Belgium – March 2, 2026 – Ardena, a specialist pharmaceutical contract development and manufacturing organizatin (CDMO) and bioanalytical contract research organization (CRO) advancing precision medicines, today [...]
Imviva Biotech Announces Acceptance of Late-Breaking Abstract Highlighting Data from Ongoing Phase 1/2 Study of CTA313 at 15th European Lupus Meeting
02/03/2026
Novel allogeneic CAR-T therapy demonstrates durable remission and immune-reset mechanism in systemic lupus erythematosus BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company [...]
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
02/03/2026
Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee representatives were [...]
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Supplemental Biologics License Application for Ziihera ® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with [...]
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
02/03/2026
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company, will continue to [...]
RadNet Acquires Gleamer, Making RadNet’s DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide
02/03/2026
Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications. Gleamer’s [...]
Trevi Therapeutics to Participate in Upcoming March Conferences
02/03/2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
02/03/2026
Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain 70% of royalties [...]
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
02/03/2026
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt [...]
Novo Nordisk A/S - share repurchase programme
02/03/2026
Bagsværd, Denmark, 2 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]

Pages